TG Therapeutics, Inc. (TGTX) recently announced projected financial outcomes for Briumvi, a cutting-edge monoclonal antibody used in treating relapsing forms of multiple sclerosis in adults. For the fourth quarter of 2024, the company projects U.S. net product revenue of $103.6 million for Briumvi, with an estimated $310 million for the entire year.
Looking ahead to fiscal year 2025, TG Therapeutics forecasts overall global revenue to be around $540 million, of which approximately $525 million is expected to come from Briumvi U.S. net product revenue.
In pre-market trading, TG's shares are experiencing an uptick of 5.38%, reaching $29.16 on the Nasdaq exchange.
